Umbilical cord blood-selected CD133+ cells exhibit vasculogenic functionality in vitro and in vivo

Marcie R. Finney, Laura R. Fanning, Matthew E. Joseph, Jonathan L. Goldberg, Nicholas J. Greco, Shyam Bhakta, Daniel G. Winter, Margaret Forster, Paul E. Scheid, Marwa Sabe, Vincent J. Pompili, Mary J. Laughlin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background aims. Current clinical trials utilize non-selected bone marrow (BM) mononuclear cells (MNC) to augment vasculo genesis within ischemic vascular beds. Recent reports have identified a diminished number and function of hemat-opoietic stem cells (HSC) from aged and diseased patients. Umbilical cord blood (UCB) provides a potential robust allo-geneic source of HSC for therapeutic vasculogenesis. Methods . MNC and magnetically isolated CD133 + cells were assessed for viability (trypan blue) and surface phenotype (flow cytometry). To test in vivo functionality of the cells, NOD/SCID mice underwent ligation of the right femoral artery followed immediately by cell injection. Blood flow recovery, necrosis, BM engraftment of human cells and histologic capillary density were determined. Cells were tested for potential mechanisms mediating the in vivo effects, including migration, cytokine secretion and angiogenic augmentation (Matrigel assays). Results. Surface expression analysis showed CD31 (PECAM) expression was greatly increased in UCB CD133+ cells compared with BM MNC. At 28 days, perfusion ratios were highest in animals receiving UCB CD133+ cells, while animals receiving BM CD133+ cells and BM MNC demonstrated perfusion ratios statistically higher than in animals treated with cytokine media alone. Animals receiving CD133+ cells showed a statistically higher capillary density, reduced severe digit necrosis and increased engraftment in the BM than animals treated with unselected BM MNC. In vitro studies showed equivalent migration to stromal-derived factor-1 (SDF-1), increased production of tumor necrosis factor alpha (TNF-α) and increased branch points with the co-incubation of CD133+ cells with human umbilical vein endothelial cells (HUVEC) in the Matrigel angiogenesis assay. Conclusions . Taken together, UCB CD133+ cells exhibit robust vasculogenic functionality compared with BM MNC in response to ischemia.

Original languageEnglish (US)
Pages (from-to)67-78
Number of pages12
JournalCytotherapy
Volume12
Issue number1
DOIs
StatePublished - 2010

Fingerprint

Fetal Blood
Bone Marrow Cells
Blood Cells
Necrosis
Stem Cells
Perfusion
Bone Marrow
Cytokines
Inbred NOD Mouse
SCID Mice
Trypan Blue
In Vitro Techniques
Human Umbilical Vein Endothelial Cells
Femoral Artery
Ligation
Blood Vessels
Flow Cytometry
Ischemia
Tumor Necrosis Factor-alpha
Clinical Trials

Keywords

  • Adult stem cells
  • Hematopoietic stem cells
  • Transplantation
  • Umbilical cord blood
  • Vasculogenesis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Cite this

Finney, M. R., Fanning, L. R., Joseph, M. E., Goldberg, J. L., Greco, N. J., Bhakta, S., ... Laughlin, M. J. (2010). Umbilical cord blood-selected CD133+ cells exhibit vasculogenic functionality in vitro and in vivo. Cytotherapy, 12(1), 67-78. https://doi.org/10.3109/14653240903300658

Umbilical cord blood-selected CD133+ cells exhibit vasculogenic functionality in vitro and in vivo. / Finney, Marcie R.; Fanning, Laura R.; Joseph, Matthew E.; Goldberg, Jonathan L.; Greco, Nicholas J.; Bhakta, Shyam; Winter, Daniel G.; Forster, Margaret; Scheid, Paul E.; Sabe, Marwa; Pompili, Vincent J.; Laughlin, Mary J.

In: Cytotherapy, Vol. 12, No. 1, 2010, p. 67-78.

Research output: Contribution to journalArticle

Finney, MR, Fanning, LR, Joseph, ME, Goldberg, JL, Greco, NJ, Bhakta, S, Winter, DG, Forster, M, Scheid, PE, Sabe, M, Pompili, VJ & Laughlin, MJ 2010, 'Umbilical cord blood-selected CD133+ cells exhibit vasculogenic functionality in vitro and in vivo', Cytotherapy, vol. 12, no. 1, pp. 67-78. https://doi.org/10.3109/14653240903300658
Finney, Marcie R. ; Fanning, Laura R. ; Joseph, Matthew E. ; Goldberg, Jonathan L. ; Greco, Nicholas J. ; Bhakta, Shyam ; Winter, Daniel G. ; Forster, Margaret ; Scheid, Paul E. ; Sabe, Marwa ; Pompili, Vincent J. ; Laughlin, Mary J. / Umbilical cord blood-selected CD133+ cells exhibit vasculogenic functionality in vitro and in vivo. In: Cytotherapy. 2010 ; Vol. 12, No. 1. pp. 67-78.
@article{fc751a0d57564afbafeea049ac6eb44c,
title = "Umbilical cord blood-selected CD133+ cells exhibit vasculogenic functionality in vitro and in vivo",
abstract = "Background aims. Current clinical trials utilize non-selected bone marrow (BM) mononuclear cells (MNC) to augment vasculo genesis within ischemic vascular beds. Recent reports have identified a diminished number and function of hemat-opoietic stem cells (HSC) from aged and diseased patients. Umbilical cord blood (UCB) provides a potential robust allo-geneic source of HSC for therapeutic vasculogenesis. Methods . MNC and magnetically isolated CD133 + cells were assessed for viability (trypan blue) and surface phenotype (flow cytometry). To test in vivo functionality of the cells, NOD/SCID mice underwent ligation of the right femoral artery followed immediately by cell injection. Blood flow recovery, necrosis, BM engraftment of human cells and histologic capillary density were determined. Cells were tested for potential mechanisms mediating the in vivo effects, including migration, cytokine secretion and angiogenic augmentation (Matrigel assays). Results. Surface expression analysis showed CD31 (PECAM) expression was greatly increased in UCB CD133+ cells compared with BM MNC. At 28 days, perfusion ratios were highest in animals receiving UCB CD133+ cells, while animals receiving BM CD133+ cells and BM MNC demonstrated perfusion ratios statistically higher than in animals treated with cytokine media alone. Animals receiving CD133+ cells showed a statistically higher capillary density, reduced severe digit necrosis and increased engraftment in the BM than animals treated with unselected BM MNC. In vitro studies showed equivalent migration to stromal-derived factor-1 (SDF-1), increased production of tumor necrosis factor alpha (TNF-α) and increased branch points with the co-incubation of CD133+ cells with human umbilical vein endothelial cells (HUVEC) in the Matrigel angiogenesis assay. Conclusions . Taken together, UCB CD133+ cells exhibit robust vasculogenic functionality compared with BM MNC in response to ischemia.",
keywords = "Adult stem cells, Hematopoietic stem cells, Transplantation, Umbilical cord blood, Vasculogenesis",
author = "Finney, {Marcie R.} and Fanning, {Laura R.} and Joseph, {Matthew E.} and Goldberg, {Jonathan L.} and Greco, {Nicholas J.} and Shyam Bhakta and Winter, {Daniel G.} and Margaret Forster and Scheid, {Paul E.} and Marwa Sabe and Pompili, {Vincent J.} and Laughlin, {Mary J.}",
year = "2010",
doi = "10.3109/14653240903300658",
language = "English (US)",
volume = "12",
pages = "67--78",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Umbilical cord blood-selected CD133+ cells exhibit vasculogenic functionality in vitro and in vivo

AU - Finney, Marcie R.

AU - Fanning, Laura R.

AU - Joseph, Matthew E.

AU - Goldberg, Jonathan L.

AU - Greco, Nicholas J.

AU - Bhakta, Shyam

AU - Winter, Daniel G.

AU - Forster, Margaret

AU - Scheid, Paul E.

AU - Sabe, Marwa

AU - Pompili, Vincent J.

AU - Laughlin, Mary J.

PY - 2010

Y1 - 2010

N2 - Background aims. Current clinical trials utilize non-selected bone marrow (BM) mononuclear cells (MNC) to augment vasculo genesis within ischemic vascular beds. Recent reports have identified a diminished number and function of hemat-opoietic stem cells (HSC) from aged and diseased patients. Umbilical cord blood (UCB) provides a potential robust allo-geneic source of HSC for therapeutic vasculogenesis. Methods . MNC and magnetically isolated CD133 + cells were assessed for viability (trypan blue) and surface phenotype (flow cytometry). To test in vivo functionality of the cells, NOD/SCID mice underwent ligation of the right femoral artery followed immediately by cell injection. Blood flow recovery, necrosis, BM engraftment of human cells and histologic capillary density were determined. Cells were tested for potential mechanisms mediating the in vivo effects, including migration, cytokine secretion and angiogenic augmentation (Matrigel assays). Results. Surface expression analysis showed CD31 (PECAM) expression was greatly increased in UCB CD133+ cells compared with BM MNC. At 28 days, perfusion ratios were highest in animals receiving UCB CD133+ cells, while animals receiving BM CD133+ cells and BM MNC demonstrated perfusion ratios statistically higher than in animals treated with cytokine media alone. Animals receiving CD133+ cells showed a statistically higher capillary density, reduced severe digit necrosis and increased engraftment in the BM than animals treated with unselected BM MNC. In vitro studies showed equivalent migration to stromal-derived factor-1 (SDF-1), increased production of tumor necrosis factor alpha (TNF-α) and increased branch points with the co-incubation of CD133+ cells with human umbilical vein endothelial cells (HUVEC) in the Matrigel angiogenesis assay. Conclusions . Taken together, UCB CD133+ cells exhibit robust vasculogenic functionality compared with BM MNC in response to ischemia.

AB - Background aims. Current clinical trials utilize non-selected bone marrow (BM) mononuclear cells (MNC) to augment vasculo genesis within ischemic vascular beds. Recent reports have identified a diminished number and function of hemat-opoietic stem cells (HSC) from aged and diseased patients. Umbilical cord blood (UCB) provides a potential robust allo-geneic source of HSC for therapeutic vasculogenesis. Methods . MNC and magnetically isolated CD133 + cells were assessed for viability (trypan blue) and surface phenotype (flow cytometry). To test in vivo functionality of the cells, NOD/SCID mice underwent ligation of the right femoral artery followed immediately by cell injection. Blood flow recovery, necrosis, BM engraftment of human cells and histologic capillary density were determined. Cells were tested for potential mechanisms mediating the in vivo effects, including migration, cytokine secretion and angiogenic augmentation (Matrigel assays). Results. Surface expression analysis showed CD31 (PECAM) expression was greatly increased in UCB CD133+ cells compared with BM MNC. At 28 days, perfusion ratios were highest in animals receiving UCB CD133+ cells, while animals receiving BM CD133+ cells and BM MNC demonstrated perfusion ratios statistically higher than in animals treated with cytokine media alone. Animals receiving CD133+ cells showed a statistically higher capillary density, reduced severe digit necrosis and increased engraftment in the BM than animals treated with unselected BM MNC. In vitro studies showed equivalent migration to stromal-derived factor-1 (SDF-1), increased production of tumor necrosis factor alpha (TNF-α) and increased branch points with the co-incubation of CD133+ cells with human umbilical vein endothelial cells (HUVEC) in the Matrigel angiogenesis assay. Conclusions . Taken together, UCB CD133+ cells exhibit robust vasculogenic functionality compared with BM MNC in response to ischemia.

KW - Adult stem cells

KW - Hematopoietic stem cells

KW - Transplantation

KW - Umbilical cord blood

KW - Vasculogenesis

UR - http://www.scopus.com/inward/record.url?scp=75449112002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75449112002&partnerID=8YFLogxK

U2 - 10.3109/14653240903300658

DO - 10.3109/14653240903300658

M3 - Article

C2 - 19878081

AN - SCOPUS:75449112002

VL - 12

SP - 67

EP - 78

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 1

ER -